A triple-hormone receptor agonist shows significant weight loss in adults with obesity
In short: A phase 2 trial of 338 adults with obesity found that a new triple-hormone-receptor agonist, retatrutide, led to substantial body weight reductions over 48 weeks. Participants receiving higher doses of the medication lost significantly more weight than those in the placebo group.
The study compared different doses of retatrutide against a placebo to assess safety and efficacy. While the drug was effective, it was associated with dose-related gastrointestinal side effects and increased heart rates. This trial provides early evidence on how the drug behaves in humans, though it was limited by its short duration and small sample size.
Why it matters: This research highlights a new pharmacological approach to weight management by targeting three different hormone receptors simultaneously.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Jastreboff et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
To cite this card, link to https://intellectplus.co.uk/app/health-research-a-triple-hormone-receptor-agonist-shows-significant-weight-l.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Medicines · More in Health · Latest · A–Z · All topics
